Welcome!

News Feed Item

Trichotillomania Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

Trichotillomania Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trichotillomania Global Clinical Trials Review, H2, 2014" provides data on the Trichotillomania clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trichotillomania. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trichotillomania. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Trichotillomania 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in North America 8
Top Countries Contributing to Clinical Trials in Middle East and Africa 9
Top Countries Contributing to Clinical Trials in Central and South America 10
Clinical Trials by G7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Drugs 21
Clinical Trial Overview of Top Institutes / Government 22
National Institute of Mental Health 22
Clinical Trial Overview of National Institute of Mental Health 22
Massachusetts General Hospital 23
Clinical Trial Overview of Massachusetts General Hospital 23
University of Chicago 24
Clinical Trial Overview of University of Chicago 24
American University of Beirut Medical Center 25
Clinical Trial Overview of American University of Beirut Medical Center 25
Yale University 26
Clinical Trial Overview of Yale University 26
University of South Florida 27
Clinical Trial Overview of University of South Florida 27
University of Sao Paulo 28
Clinical Trial Overview of University of Sao Paulo 28
Hamilton Health Sciences 29
Clinical Trial Overview of Hamilton Health Sciences 29
University of Pennsylvania 30
Clinical Trial Overview of University of Pennsylvania 30
Stanford University 31
Clinical Trial Overview of Stanford University 31
Five Key Clinical Profiles 32
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 51

List of Tables
Trichotillomania Therapeutics, Global, Clinical Trials by Region, 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries, 2014* 8
Trichotillomania Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 9
Trichotillomania Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 10
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 20
Trichotillomania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 22
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 23
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2014* 24
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by American University of Beirut Medical Center, 2014* 25
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 26
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of South Florida, 2014* 27
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 28
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 29
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 30
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 31

List of Figures
Trichotillomania Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 8
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 20
GlobalData Methodology 50


Read the full report:
Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp emp...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
As popularity of the smart home is growing and continues to go mainstream, technological factors play a greater role. The IoT protocol houses the interoperability battery consumption, security, and configuration of a smart home device, and it can be difficult for companies to choose the right kind for their product. For both DIY and professionally installed smart homes, developers need to consider each of these elements for their product to be successful in the market and current smart homes.
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant th...
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...